<DOC>
	<DOC>NCT00556998</DOC>
	<brief_summary>This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole. This will help establish voriconazole dosing recommendations for adolescents.</brief_summary>
	<brief_title>A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Subjects who are expected to develop neutropenia following chemotherapy. Subjects who require treatment for the prevention of systemic fungal infection. Subjects with a history of severe intolerance of azole antifungal agents. Subjects with documented bacterial or viral infection at the time of study entry who are not responding to appropriate treatment against the infection.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>pharmacokinetics and safety data of voriconazole in immunocompromised adolescents</keyword>
</DOC>